经过冷冲击的瘤重编程的无声敏感抗原呈现细胞通过T细胞和NK细胞免疫改善了通过T细胞和NK细胞进行的无声免疫疗法
Xindi Qian1,2,3, Wenzhe Yi2,4, Wenlu Yan2,4
1Department of Medical Ultrasound and Center of Minimally Invasive Treatment for Tumor, Shanghai Tenth People's Hospital, Ultrasound Research and Education Institute, School of Medicine, Tongji University, Shanghai, 200072, China.
这项研究引入了一种新的超声波敏感系统,使用工程瘤细胞来增强自然杀伤细胞 (NK) 和T细胞免疫力,以改善癌症免疫疗法. 该方法在三阴性乳腺癌模型中增强了抗瘤反应和存活率.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 生物医学工程 生物医学工程
背景情况:
- 超声波疗法对癌症免疫疗法有希望,但由于有限的共刺激和MHC-I表达在瘤细胞上,它面临着挑战.
- 自然杀手 (NK) 细胞介导的先天性免疫和T细胞介导的适应性免疫对于有效的癌症免疫疗法至关重要.
研究的目的:
- 开发一种声敏系统,以增强NK细胞和T细胞的反应,以改善癌症免疫治疗.
- 为了利用抗原呈现细胞 (APC) 类瘤细胞来增强对癌症的免疫反应.
主要方法:
- 用基因工程修改的瘤细胞与共刺激分子进行了修改,并通过点击化学与声敏剂 (血红素单甲) 结合,形成DPNLs.
- DPNL的设计是针对瘤和排水淋巴结的.
- 超声波用于激活NK细胞和刺激瘤排水淋巴结中的T细胞.
主要成果:
- DPNLs系统成功地激活了NK细胞介导的先天免疫力,并通过共同刺激分子刺激了T细胞.
- 在三阴性乳腺癌模型中,用DPNLs和PD-L1抗体进行组合治疗显著延长了生存时间,并抑制了肺转移.
- 该系统展示了精确的声敏剂传递和增强的免疫细胞激活.
结论:
- 这种声敏系统通过增强先天性和适应性免疫反应,为声免疫疗法提供了一个有前途的策略.
- 工程DPNLs有效地增强抗瘤免疫力,为癌症治疗提供了潜在的新途径.
- 这项研究强调了利用类似APC的瘤细胞进行向癌症免疫治疗的潜力.
更多相关视频
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
09:07Sonodynamic Therapy for the Treatment of Glioblastoma Multiforme in a Mouse Model Using a Portable Benchtop Focused Ultrasound System
Published on: February 10, 2023
相关概念视频
Tumor Immunotherapy
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
